Aleksey Matveyenko

Aleksey Matveyenko, Ph.D., is a Professor of Physiology at Mayo Clinic in Rochester, Minnesota, with a primary appointment as a Consultant in the Department of Physiology & Biomedical Engineering and a joint appointment in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine. He leads the Islet Regeneration Laboratory, focusing on translational and basic research to understand and combat beta cell failure in diabetes.

His research interests center on the pathophysiology of diabetes, particularly the mechanisms linking circadian disruption to type 2 diabetes, the role of intracellular circadian clocks (clock genes) in beta cell function and survival, the impact of T2DM-associated genetic loci (e.g., TCF7L2, MTNR1B) on islet cell physiology, and the molecular basis of pancreatic cancer-induced diabetes. His lab employs an integrative approach combining cellular, molecular, biochemical, and in vivo physiological studies using rodent models of diabetes and obesity.

Dr. Matveyenko has been recognized with several prestigious awards, including the Innovation Accelerator Award (2023, 2024) and the J.W. Kieckhefer Professorship in Regenerative Medicine (2023). These honors reflect his innovative contributions to regenerative approaches for type 1 diabetes and translational research. He actively collaborates with clinicians and researchers such as Adrian Vella, M.D., and Suresh T. Chari, M.D., to bridge molecular insights with clinical applications.

Although specific grant details and student names are not listed in the provided text, his laboratory is deeply involved in postdoctoral training and translational research programs at Mayo Clinic. His work is integral to the Research Center for Regenerative Biotherapeutics and aligns with broader institutional efforts in endocrinology and regenerative medicine.

The Islet Regeneration Laboratory, under Dr. Matveyenko’s leadership, is dedicated to developing novel therapeutic and preventive strategies to restore and regenerate pancreatic beta cells, aiming to address the global epidemic of diabetes mellitus. The lab’s focus on gene-environment interactions and circadian regulation positions it at the forefront of diabetes pathophysiology research.